SCHEMBL5808588

SCHEMBL5808588

Nc1cccc(NC2=C(Cl)C(=O)c3ccccc3C2=O)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 12/20 0.68
▸ RAB9A P51151 10/20 0.68
▸ HTT P42858 10/20 0.68
▸ KMT2A Q03164 10/20 0.68
▸ NPSR1 Q6W5P4 8/20 0.68
▸ MEN1 O00255 8/20 0.68
▸ MAPK1 P28482 7/20 0.68
▸ NPC1 O15118 7/20 0.68
▸ ATM Q13315 5/20 0.68
▸ LMNA P02545 5/20 0.68
▸ GAA P10253 4/20 0.68
▸ MITF O75030 3/20 0.68
▸ SMN1; SMN2 Q16637 2/20 0.68
▸ XBP1 P17861 1/20 0.68
▸ ALDH1A1 P00352 6/20 0.63
▸ CDC25A P30304 3/20 0.63
▸ CDC25B P30305 3/20 0.63
▸ MCL1 Q07820 3/20 0.63
▸ NSD2 O96028 2/20 0.63
▸ MAP2K7 O14733 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7240445 0.82 MAPT (0.74) MAPTRAB9AHTTKMT2ANPSR1
SCHEMBL29633261 0.81 MAPT (1.00) MAPTRAB9AHTTKMT2ANPSR1
SCHEMBL6506683 0.81 MAPT (1.00) MAPTRAB9AHTTKMT2ANPSR1
SCHEMBL24327533 0.78 MAPT (0.44) MAPTRAB9AHTTKMT2ANPSR1
SCHEMBL1243522 0.78 MAPT (0.73) MAPTRAB9AHTTKMT2ANPSR1
SCHEMBL11786902 0.76 GNG2 (0.67) MAPTKMT2AMEN1MAPK1LMNA
SCHEMBL32664539 0.75 MAPT (0.79) MAPTRAB9AHTTKMT2ANPSR1
SCHEMBL31682570 0.75 RAB9A (0.62) MAPTRAB9AHTTKMT2ANPSR1
SCHEMBL7118329 0.75 MAPT (0.59) MAPTRAB9AHTTKMT2ANPSR1
SCHEMBL1242311 0.74 MAPT (0.67) MAPTRAB9AHTTKMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11084786-B2 Compounds and pharmaceutical composition associated with ubiquitination-proteasome system CALGENT BIOTECHNOLOGY CO., LTD. (TW) 2021-08-10 — — US disclosed
US-11084786-B2 Compounds and pharmaceutical composition associated with ubiquitination-proteasome system CALGENT BIOTECHNOLOGY CO., LTD. (TW) 2021-08-10 — — US disclosed
US-20200385344-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM CALGENT BIOTECHNOLOGY CO., LTD. (TW) 2020-12-10 — — US disclosed
US-20200385344-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM CALGENT BIOTECHNOLOGY CO., LTD. (TW) 2020-12-10 — — US disclosed
US-10745350-B2 Compounds and pharmaceutical composition associated with ubiquitination-proteasome system CALGENT BIOTECHNOLOGY CO., LTD. (TW) 2020-08-18 — — US disclosed
US-10745350-B2 Compounds and pharmaceutical composition associated with ubiquitination-proteasome system CALGENT BIOTECHNOLOGY CO., LTD. (TW) 2020-08-18 — — US disclosed
EP-3328368-B1 COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM BRIDGENT BIOTECHNOLOGY INC (TW) 2020-07-15 — — EP disclosed
EP-3328368-B1 COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM BRIDGENT BIOTECHNOLOGY INC (TW) 2020-07-15 — — EP disclosed
US-20190144383-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM CALGENT BIOTECHNOLOGY CO., LTD. (TW) 2019-05-16 — — US disclosed
US-20190144383-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM CALGENT BIOTECHNOLOGY CO., LTD. (TW) 2019-05-16 — — US disclosed
EP-3328368-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM Taipei Medical University (TW) 2018-06-06 — — EP disclosed
WO-2017020030-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM TAIPEI MEDICAL UNIVERSITY (TW) 2017-02-02 — — WO disclosed
WO-2017020030-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM TAIPEI MEDICAL UNIVERSITY (TW) 2017-02-02 — — WO disclosed
WO-2006011136-A9 NOVEL NAPHTHOQUINONE DERIVATIVES AND USES THEREOF VELOPMENT AUTHORITY BEN GURION (IL) 2006-04-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190144383-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM PSMC1, PSME3, PSMB1 MAPT 308/4885RAB9A 1884/4885HTT 209/4885
US-10745350-B2 Compounds and pharmaceutical composition associated with ubiquitination-proteasome system PSMC1, PSME3, PSMB1 MAPT 308/4885RAB9A 1884/4885HTT 209/4885
US-11084786-B2 Compounds and pharmaceutical composition associated with ubiquitination-proteasome system PSMC1, PSME3, PSMB1 MAPT 308/4885RAB9A 1884/4885HTT 209/4885
US-20200385344-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM PSMC1, PSME3, PSMB1 MAPT 308/4885RAB9A 1884/4885HTT 209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback